Sector News

Novo Nordisk’s Wegovy gets a surprise endorsement from Twitter’s soon-to-be owner Elon Musk

October 15, 2022
Life sciences

How do you solve a problem like Elon Musk? Well, when it comes to his weight, there seems to be a simple answer: Novo Nordisk’s Wegovy.

Musk, who runs several major companies including SpaceX and electric car firm Tesla and is now set—after a long legal tussle—to buy Twitter, said on the social media platform in response to a question about his recent weight loss that it was down to “Fasting” and, in a later tweet, “And Wegovy.”

Wegovy is Novo Nordisk’s injectable form of GLP-1 drug semaglutide, the ingredient in its diabetes franchise Ozempic and Rybelsus.

The FDA approved Wegovy last summer for chronic weight management in adults with obesity or who are overweight with at least one weight-related condition (such as high blood pressure, Type 2 diabetes or high cholesterol) with a BMI of 27 or more or in those with a BMI of 30 or greater in general.

While some nice free advertising for Novo, it isn’t clear whether Musk should, according to the drug’s approval, in fact be using the drug. For that reason, these kinds of unexpected endorsements can be a double-edged sword for companies.

In fact earlier this year, a report out by Variety claimed that a number of celebrities are paying big bucks to use Ozempic but in a slightly different dose to tap its weight-loss effects.

Musk is not a spokesperson for the company and a Novo Nordisk spokesperson told Fierce Pharma Marketing that “we were not aware of Elon Musk’s use of Wegovy before he shared this information publicly.”

Wegovy’s approval could be a boon for obesity drugs, which have been few and far between despite there being a potentially lucrative market.

Heart safety concerns have hampered many meds over the past 20 years, but Wegovy appears to be bucking the trend, and is set to become a blockbuster later this decade.

It does, however, have a potential rival in Eli Lilly’s tirzepatide, but just this month got a rolling submission off to the FDA for obesity. The drug was approved earlier this year for Type 2 diabetes approval and is branded as Mounjaro.

By Ben Adams

Source: fiercepharma.com

comments closed

Related News

March 19, 2023

Ferring Pharmaceuticals’ 1st in class C.diff Treatment, Rebyota, experiences a positive early launch ahead of potential competition

Life sciences

With a first to market advantage, Ferring’s Rebyota has seen early positive adoption from gastroenterologists and infectious disease specialist in the first month post-launch. As part of their Launch Dynamix™: C.diff service, Spherix reports, while new monthly initiations are modest, a majority of physicians trialing Rebyota report high satisfaction.

March 19, 2023

UCB enters drug discovery collaboration with Aitia

Life sciences

Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia. The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder.

March 19, 2023

Novo, Medtronic add $25M in fuel to FIRE1 and its heart failure monitoring device

Life sciences

Foundry Innovation & Research 1—known by its much catchier acronym, FIRE1—announced Wednesday the close of a $25 million financing round. It was led by a pair of new investors in the company: Andera Partners and Novo Holdings, the holding and investment company that serves as the controlling shareholder for Novo Nordisk and Novozymes.

How can we help you?

We're easy to reach